← Back to Search

Monoclonal Antibodies

Visilizumab for Graft-versus-Host Disease

Phase 2

Waitlist Available

Research Sponsored by Fred Hutchinson Cancer Research Center

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Patients must have adequate renal, hepatic, cardiac function and hematologic values

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 5 years

Awards & highlights

Study Summary

This trial is testing a new monoclonal antibody to see if it's effective in treating GVHD in patients who haven't responded to other treatments.

Who is the study for?

This trial is for patients with Graft Versus Host Disease (GVHD) who haven't improved after standard treatments. They must have had a transplant and show no response to previous therapies by day +100 post-transplant, with good kidney, liver, heart function, and blood counts.Check my eligibility

What is being tested?

The study tests Visilizumab, an experimental antibody for treating GVHD that's resistant to steroids. Participants can keep taking their current immunosuppressants at unchanged doses while in the trial which will take place across up to 20 US sites.See study design

What are the potential side effects?

Potential side effects of Visilizumab may include allergic reactions due to the infusion of the drug, increased risk of infections because it suppresses the immune system, and possibly other organ-related complications.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

My kidney, liver, heart functions, and blood counts are within normal ranges.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 5 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 5 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

0 / 1Eligibility criteria met

Find a Location

Who is running the clinical trial?

Fred Hutchinson Cancer Research CenterLead Sponsor

443 Previous Clinical Trials

148,165 Total Patients Enrolled

Fred Hutchinson Cancer CenterLead Sponsor

556 Previous Clinical Trials

1,343,188 Total Patients Enrolled

1 Trials studying Graft-versus-Host Disease

10 Patients Enrolled for Graft-versus-Host Disease

Facet BiotechIndustry Sponsor

21 Previous Clinical Trials

1,417 Total Patients Enrolled

Media Library

Visilizumab (Monoclonal Antibodies) Clinical Trial Eligibility Overview. Trial Name: NCT00032279 — Phase 2

Graft-versus-Host Disease Research Study Groups:

Graft-versus-Host Disease Clinical Trial 2023: Visilizumab Highlights & Side Effects. Trial Name: NCT00032279 — Phase 2

Visilizumab (Monoclonal Antibodies) 2023 Treatment Timeline for Medical Study. Trial Name: NCT00032279 — Phase 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How hazardous is this treatment for those individuals engaging in it?

"Our team at Power rate the safety of this treatment as a 2 due to its Phase 2 status. This suggests that while there is data indicating an acceptable level of hazard, efficacy remains unconfirmed."

Answered by AI

Is this research opportunity open to individuals younger than 65 years old?

"The requirements for participation in this study mandates that potential candidates must be between the ages of 0 and 65. Specifically, there are 63 studies targeting minors under 18-years of age, as well as 145 trials focusing on those above senior citizen status."

Answered by AI

Are any new participants signing up to join this trial at the present time?

"Unfortunately, the details posted on clinicaltrials.gov reveal that this trial is no longer recruiting participants; its initial post date was March 1st 2002 with a last edit on June 23rd 2005. However, there are 169 other studies actively seeking individuals to join in as of now."

Answered by AI

To what extent is this research trial being conducted across hospitals?

"Currently, this research initiative is enrolling patients at 17 separate sites dispersed across the United States. These include St. Louis, Cleveland and Seattle as well as 14 other locations; selecting a trial site closest to you can help reduce travel costs associated with enrollment."

Answered by AI

Who meets the eligibility criteria for this research trial?

"This clinical trial seeks 80 individuals, aged 0 to 0 with existing graft-versus-host disease. In addition, applicants must have failed prior treatments by day +100 posttransplantation; possess adequate renal, hepatic and cardiac functions as well as hematological values; display Grade II to IV GVHD symptoms such as skin hardening, joint contraction, oral ulcerations or diarrhoea."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Research Study of Visilizumab for Treatment of Glucocorticoid- Refractory Graft Versus Host Disease

2002. "Research Study of Visilizumab for Treatment of Glucocorticoid- Refractory Graft Versus Host Disease". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT00032279.

All > Graft Vs Host Disease